Regeneron Pharmaceuticals (REGN) Announces Approval of Dupixent in the US

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that its Dupixent has been approved as the only targeted medicine to treat Bullous Pemphigoid in the United States.

Bullous pemphigoid is a chronic disease characterized by intense itching, painful blisters, skin lesions, and redness. Until now, treatment options for Bullous pemphigoid were limited and often involved suppressing the immune system with oral corticosteroids, which can add to the disease burden, especially in elderly patients.

Regeneron Pharmaceuticals (REGN) Announces Approval of Dupixent in the US

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

Dupixent is the first and only targeted medicine approved in the United States addressing two central drivers of type 2 inflammation. The treatment reduces itch, improves disease symptoms, and helps some patients achieve sustained remission while decreasing the need for oral corticosteroids.

The approval for Regeneron Pharmaceuticals, Inc.’s  (NASDAQ:REGN) Dupixent was based on results from the pivotal ADEPT Phase 2/3 clinical trial, which showed 18.3% of Dupixent-treated patients achieved sustained disease remission. Moreover, the regulatory submissions for Dupixent in BP are also under review in other regions, including the EU, Japan, and China.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.